Sponsor or institution
Clinical trials and research at Vasarya Therapeutics, INC.
As of November 12, 2026, Find a Trial lists 3 NIH-funded research projects at this institution, with $2.6 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 3NIH research projects
NIH-funded research (3)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Targeted antibody treatment for idiopathic pulmonary fibrosis
A new antibody drug designed to stick to and calm scarring in the lungs for people with idiopathic pulmonary fibrosis (IPF).
-
Developing a new treatment for Idiopathic Pulmonary Fibrosis
This study is testing a new drug called VSR-H5 that aims to help people with Idiopathic Pulmonary Fibrosis (IPF) by targeting only the damaged areas of their lungs, with the hope of improving their health without causing the side effects that come with current treatments.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.